Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD

Weng, Ching-FuChing-FuWengCHIEN-CHIH WUWu, Mei-HsuanMei-HsuanWuFANG-JU LIN2023-06-212023-06-212023-040012-3692https://scholars.lib.ntu.edu.tw/handle/123456789/633022Researchers have yet to obtain conclusive evidence differentiating among fixed-dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) for COPD in terms of real-world clinical outcomes.enCOPD; acute exacerbation; cardiovascular event; fixed-dose combinations; long-acting muscarinic antagonists; long-acting β(2)-agonists[SDGs]SDG3Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPDjournal article10.1016/j.chest.2022.11.027364426622-s2.0-85150800296WOS:000979916200001https://api.elsevier.com/content/abstract/scopus_id/85150800296